US FDA’s Breakthrough Designation Pace Slows, But Topics Broaden
Executive Summary
The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.
You may also be interested in...
US FDA AdComm For Vertex’s Sickle Cell Gene Therapy ‘Not A Concern’
The US biotech revealed the US Food and Drug Administration would be holding an advisory committee meeting for exa-cel during its second quarter earnings, but analysts are unfazed by the news amid robust revenues and raised guidance.
GSK's Jemperli First-Line Endometrial Cancer Approval Fillip Ahead Of Keytruda Advance
The major’s PD-L1 inhibitor is the first to win US approval for the treatment of first-line endometrial cancer in combination with chemotherapy, but an unsurprisingly narrow label means rival Merck & Co.’s Keytruda could still make a splash in this indication.
Sanofi’s Dupixent Has Greater Benefit In COPD Patients With Higher Type II Inflammation
The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.